Anticoagulant Reversal Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026

Published on : Nov-2019 | List of Tables : 22 | List of Figures : 93 | No. of Pages : 170 | Report Code : FACT4338MR | Format : ppt pdf Excel Word

Sales of Anticoagulant Reversal Drugs to Soar in North America, While APAC Sees Moderate Growth

Favourable regulatory scenario, especially in developed economies of North America and Europe, has inadvertently created a highly conducive environment for the growth of the anticoagulant reversal drugs market. However, steep prices of anticoagulant reversal drugs will result in moderate sales in price-sensitive countries of APAC and MEA. Taking a cue from this high-cost concern, regional and local players are looking at increasing their presence in the anticoagulant reversal drugs market through the introduction of generic drugs. Their global counterparts, however, are increasing investments towards the development of blockbuster drugs.

All-in-all, the anticoagulant reversal drugs market is projected to offer equal growth opportunities to global, regional, and local players, given the fragmented nature of the market space.

opportunity analysis in global anticoagulant reversal drugs market by product

For detailed insights on market taxonomy, request a sample copy of the report here.

Popularity of Idarucizumab to Lose Vigour to Andexxa

Sales of Idarucizumab increased 19% Y-o-Y in 2019 over 2018. However, according to the estimation of a seasoned analyst at Fact.MR, year-over-year sales of the same drug will witness a sharp decrease of 11% in 2026 over 2025. This drug achieved immediate traction in the anticoagulant reversal drugs market, owing to the absence of an equivalent reversal agent. The downward sales curve traced by Idarucizumab can be attributable to the increasing popularity of Andexxa, which received approval from the U.S. Food and Drug Administration in 2018.

There has been a steep increase in the preference for Andexxa over Idarucizumab, given the recognition received by the novel reversal agent as an orphan drug. In the future, the popularity of this drug is projected to witness exponential growth, as there is an absence of effective drugs in the anticoagulant reversal drugs market.

Introduction of New Technology Add-on Payment to Underpin Sales

As the challenge regarding the limited penetration of effective drugs came into light, cost-prohibitive nature of reversal agents was found to have a negative influence on their sales. Governments of developed countries launched a new payment system - new technology add-on payment (NTAP) - to promote the adoption of new and expensive drugs. The reimbursement plan, in turn, is projected to underpin the expenses of patients and drive profitability to the anticoagulant reversal drugs market during the forecast period. Under this plan, the Praxbind drug is eligible for availing complete reimbursement in England, Wales, and Ireland, without the need for full approval by Health Technology Appraisal authorities. On the backdrop of favourable reimbursement plans present in the anticoagulant reversal drugs market, a wide base of patients is expected to avail these benefits, and, in turn, amplify sales prospects.

Market Players Strive to Meet Unmet Clinical Demands

The application of reversal agents has witnessed a marked increase in recent times, in life-threatening conditions or cases with uncontrolled bleeding. Manufacturers in the anticoagulant reversal drugs market are sensing a rise in demand and navigating their research & development endeavours to bridge the underlying gaps present in these therapeutics. This is leading to a robust pipeline for anticoagulant reversal drugs, especially in Europe and North America, given the high concentration of leading players in these regions. In addition, there has been an increase in governments’ financial aid towards promoting the production of effective therapeutics, which is further paving way for the introduction of novel drugs in the anticoagulant reversal drugs market. Fast-track approval of blockbuster drugs is enabling players in the anticoagulant reversal drug market to achieve faster time-to-market, which is predicted to extend the scope of the market.

analysis of key distribution channels in global anticoagulant reversal drugs market

For detailed regional analysis, request a sample copy of the report here.

Sales through Hospital Pharmacies will Remain High in North America

The evolving landscape is adding new revenue streams for the anticoagulant reversal drugs market; however, hospital pharmacies are projected to account for ~65% of the total sales by 2026. The increasing prevalence of atrial fibrillation, intracranial haemorrhages, and gastrointestinal haemorrhages is projected to boost the demand for anticoagulant reversal drugs. North America is expected to close a majority of sales through anticoagulant reversal drugs. The region is home to a large number of hospitals offering quality healthcare services. With the growing number of surgeries, the sales of anticoagulant reversal drugs through hospital pharmacies are on the rise. In addition, recent times have witnessed a surge in the number of outpatient care centres and ambulatory surgical centres, which is projected to strengthen the demand for anticoagulant reversal drugs.

Request research methodology of this report.

Anticoagulant Reversal Drugs Market - Scope of the Study

The study on the anticoagulant reversal drugs market is an exclusive report published by Fact.MR, which provides information regarding the key growth influencers of the landscape. This study offers insights on the growth of the anticoagulant reversal drugs market, by analysing the historical data for the period of 2016 - 2019, and 2020 - 2026 as the forecast period. Estimation of the revenue of the anticoagulant reversal drugs market has been carried out in terms of value (US$ Mn). This exclusive report focuses on offering information on the key trends that are likely to influence the growth of the anticoagulant reversal drugs market, in addition to crucial microscopic and macroeconomic growth indicators. The incisive report offers the key dynamics, along with their influence on the value chain, which is projected to positively impact the future growth of the anticoagulant reversal drugs market.

The study also includes a detailed section dedicated to impeders that could challenge the growth of players in the anticoagulant reversal drugs market. The report unfolds profitable opportunities for market players, which can be leveraged to consolidate their position in the global market. With a view of aiding stakeholders in the anticoagulant reversal drugs market, the study includes a detailed section on the competition landscape of the anticoagulant reversal drugs market. The study provides a dashboard view of the report, with a detailed comparison of players operating in the anticoagulant reversal drugs market, based on total revenue, market presence, and key developments. In addition to this, key strategies and recent developments implemented by players in the anticoagulant reversal drugs market have also been included in this comprehensive study.

Anticoagulant Reversal Drugs Market - Assessment of Key Segments

Authors of the report have segmented the anticoagulant reversal drugs market into key categories in order to study the market at a microscopic level. The key segments considered while bifurcating the anticoagulant reversal drugs market include:

Product

Distribution Channel

Region

Prothrombin Complex Concentrates

Hospital Pharmacies

North America

Vitamin K

Retail Pharmacies

Europe

Protamine

Others

Latin America

Tranexamic Acid

 

Asia Pacific

Idarucizumab

 

Middle East & Africa

Andexxa

 

 

Others

 

 

Besides magnifying focus on the crucial segments, this exclusive study also offers information on the anticoagulant reversal drugs market at a country level, to identify the underlying opportunities available for players in the anticoagulant reversal drugs market for the forecast period. Among all the estimated data, the report also includes Y-o-Y growth projections, which can help market players in comprehending the precise trajectory at which the anticoagulant reversal drugs market has been growing.

Key companies profiled in the anticoagulant reversal drugs market include Perosphere Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Portola Pharmaceuticals, Inc., CSL Limited, Octapharma AG, Amneal Pharmaceuticals Inc., Bausch Health Companies, Inc., Fresenius Kabi AG, and Pfizer, Inc.

Anticoagulant Reversal Drugs Market - Research Methodology

The anticoagulant reversal drugs market has been evaluated by taking a top-down and bottom-up approach. Demand, geographical presence, distribution strategies by manufacturers, and initiatives taken by governments and NGOs are various factors considered while estimating the revenue of the anticoagulant reversal drugs market, and thus, reaching global numbers. The study on the anticoagulant reversal drugs market is further validated through extensive primary research on the data extracted from exhaustive secondary research.

In order to conduct secondary research, annual company reports, company websites, data from the World Health Organization (WHO), SEC filings, press releases, investor presentations, and other similar resources were studied. Both, the top-down and bottom-up approaches were undertaken by analysts of the report to find accurate data regarding the growth of the anticoagulant reversal drugs market. To validate the information compiled through secondary research, interviews with key opinion leaders and subject matter experts were scheduled. The analysis aims at studying the business environment, unmet needs of consumers, key restraints, historical sales pattern, and investment landscape. In addition to this, authors of the report also had email and telephonic interactions with the senior management of leading and prominent companies to confirm the size, growth trends, and future outlook of the anticoagulant reversal drugs market.

1. Preface 

    1.1. Report Scope and Market Segmentation 

    1.2. Research Highlights

2. Assumptions and Acronyms Used

3. Research Methodology

4. Executive Summary

5. Market Overview

    5.1. Product Overview

    5.2. Market Dynamics

        5.2.1. Drivers

            5.2.1.1. Rise in the prevalence of atrial fibrillation in aging population 

            5.2.1.2. Increase in the prevalence of ICH and GI hemorrhages

            5.2.1.3. NTAP status for specific drugs

        5.2.2. Restraints

            5.2.2.1. Challenges associated with the development of anticoagulant reversal drugs 

            5.2.2.2. Risk associated with reversing anticoagulation 

        5.2.3. Opportunities

            5.2.3.1. Unmet clinical needs

            5.2.3.2. Untapped market in emerging economies 

        5.2.4. Global Anticoagulant Reversal Drugs Market Value (US$ Mn) Forecast, 2016?2026

        5.2.5. Global Anticoagulant Reversal Drugs Market Outlook

        5.2.6. Key Industry Developments

        5.2.7. Regulatory Scenario

        5.2.8. Reimbursement Scenario

        5.2.9. Pipeline Analysis

        5.2.10. Healthcare Overview 

6. Global Anticoagulant Reversal Drugs Market Analysis, by Product 

    6.1. Introduction

    6.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product 

    6.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016?2026

        6.3.1. Prothrombin Complex Concentrates (PCC)

        6.3.2. Vitamin K

        6.3.3. Protamine

        6.3.4. Tranexmic Acid

        6.3.5. Idarucizumab

        6.3.6. Andexxa

        6.3.7. Others

    6.4. Market Attractiveness, by Product 

7. Global Anticoagulant Reversal Drugs Market Analysis, by Distribution Channel

    7.1. Introduction

    7.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel

    7.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies 

        7.3.3. Others

    7.4. Market Attractiveness, by Distribution Channel

8. Global Anticoagulant Reversal Drugs Market Analysis, by Region

    8.1. Introduction

    8.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Anticoagulant Reversal Drugs Market Analysis

    9.1. Key Findings

    9.2. North America Anticoagulant Reversal Drugs Market Value Forecast, by Country, 2016?2026

        9.2.1. U.S.

        9.2.2. Canada

    9.3. North America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026

        9.3.1. Prothrombin Complex Concentrates (PCC)

        9.3.2. Vitamin K

        9.3.3. Protamine

        9.3.4. Tranexmic Acid

        9.3.5. Idarucizumab

        9.3.6. Andexxa

        9.3.7. Others

    9.4. North America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026

        9.4.1. Hospital Pharmacies

        9.4.2. Retail Pharmacies 

        9.4.3. Others

    9.5. North America Market Attractiveness Analysis

        9.5.1. By Country

        9.5.2. By Product 

        9.5.3. By Distribution Channel

10. Europe Anticoagulant Reversal Drugs Market Analysis

    10.1. Key Findings

    10.2. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026

        10.2.1. U.K.

        10.2.2. Germany

        10.2.3. France

        10.2.4. Italy

        10.2.5. Spain

        10.2.6. Rest of Europe

    10.3. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026

        10.3.1. Prothrombin Complex Concentrates (PCC)

        10.3.2. Vitamin K

        10.3.3. Protamine

        10.3.4. Tranexmic Acid

        10.3.5. Idarucizumab

        10.3.6. Andexxa

        10.3.7. Others

    10.4. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies 

        10.4.3. Others

    10.5. Europe Market Attractiveness Analysis

        10.5.1. By Country/Sub-region

        10.5.2. By Product 

        10.5.3. By Distribution Channel

11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis

    11.1. Key Findings

    11.2. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026

        11.2.1. China

        11.2.2. Japan

        11.2.3. India

        11.2.4. Australia

        11.2.5. Rest of Asia Pacific 

    11.3. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026

        11.3.1. Prothrombin Complex Concentrates (PCC)

        11.3.2. Vitamin K

        11.3.3. Protamine

        11.3.4. Tranexmic Acid

        11.3.5. Idarucizumab

        11.3.6. Andexxa

        11.3.7. Others

    11.4. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies 

        11.4.3. Others

    11.5. Asia Pacific Market Attractiveness Analysis

        11.5.1. By Country/Sub-region

        11.5.2. By Product 

        11.5.3. By Distribution Channel

12. Latin America Anticoagulant Reversal Drugs Market Analysis

    12.1. Key Findings

    12.2. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026

        12.2.1. Brazil 

        12.2.2. Mexico

        12.2.3. Rest of Latin America

    12.3. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026

        12.3.1. Prothrombin Complex Concentrates (PCC)

        12.3.2. Vitamin K

        12.3.3. Protamine

        12.3.4. Tranexmic Acid

        12.3.5. Idarucizumab

        12.3.6. Andexxa

        12.3.7. Others

    12.4. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies 

        12.4.3. Others

    12.5. Latin America Market Attractiveness Analysis

        12.5.1. By Country/Sub-region

        12.5.2. By Product 

        12.5.3. By Distribution Channel

13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis

    13.1. Key Findings

    13.2. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2016?2026

        13.2.1. GCC Countries 

        13.2.2. South Africa 

        13.2.3. Israel 

        13.2.4. Rest of Middle East & Africa

    13.3. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2016–2026

        13.3.1. Prothrombin Complex Concentrates (PCC)

        13.3.2. Vitamin K

        13.3.3. Protamine

        13.3.4. Tranexmic Acid

        13.3.5. Idarucizumab

        13.3.6. Andexxa

        13.3.7. Others

    13.4. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2016–2026

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies 

        13.4.3. Others

    13.5. Middle East & Africa Market Attractiveness Analysis

        13.5.1. By Country/Sub-region

        13.5.2. By Product 

        13.5.3. By Distribution Channel

14. Competitive Landscape

    14.1. Competition Matrix

    14.2. Anticoagulant Reversal Drugs Market Share Analysis, by Company (2018)

    14.3. Company Profiles

        14.3.1. Bausch Health Companies, Inc. 

            14.3.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.1.2. Financial Overview 

            14.3.1.3. Product Portfolio

            14.3.1.4. SWOT Analysis

            14.3.1.5. Strategic Overview

        14.3.2. Pfizer, Inc. 

            14.3.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.2.2. Financial Overview 

            14.3.2.3. Product Portfolio

            14.3.2.4. SWOT Analysis

        14.3.3. Fresenius Kabi AG 

            14.3.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.3.2. Financial Overview 

            14.3.3.3. Product Portfolio

            14.3.3.4. SWOT Analysis

        14.3.4. Amneal Pharmaceuticals, Inc. 

            14.3.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. SWOT Analysis

            14.3.4.4. Strategic Overview

        14.3.5. Boehringer Ingelheim GmbH 

            14.3.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.5.2. Financial Overview 

            14.3.5.3. Product Portfolio

            14.3.5.4. SWOT Analysis

            14.3.5.5. Strategic Overview

        14.3.6. CSL Limited 

            14.3.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.6.2. Financial Overview 

            14.3.6.3. Product Portfolio

            14.3.6.4. SWOT Analysis

        14.3.7. Octapharma AG 

            14.3.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.7.2. Financial Overview 

            14.3.7.3. Product Portfolio

            14.3.7.4. SWOT Analysis

        14.3.8. Portola Pharmaceuticals, Inc.

            14.3.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.8.2. Financial Overview 

            14.3.8.3. Product Portfolio

            14.3.8.4. SWOT Analysis

            14.3.8.5. Strategic Overview

        14.3.9. Perosphere Pharmaceuticals, Inc. (acquired by AMAG Pharmaceuticals, Inc.)

            14.3.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)

            14.3.9.2. Product Portfolio

            14.3.9.3. SWOT Analysis

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Anticoagulant Reversal Drugs Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2020 to 2026